Related Experiment Video
Updated: May 22, 2026
Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
Published on: September 19, 2019
Tumor heterogeneity and its implication for drug delivery
1Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah, Salt Lake City, UT 84108, USA.
Abstract:
Evidence continues to accumulate that patient tumors contain heterogeneous cell populations, each of which may contribute differently in extent and mechanism to the progression of malignancy. However, the field of tumor drug delivery research, while continually presenting new and innovative approaches, in many ways continues to operate on the premise that essentially all tumor cells are identical. In some in vivo models, xenograft tumors using cell lines may actually be comparatively homogeneous, and thus result in overly encouraging results when a particular drug or delivery system is reported to successfully treat tumors in mice. It is well known, however, that many drugs that show success in preclinical studies will fail in clinical trials. Tumor heterogeneity is possibly one of the most significant factors that most treatment methods fail to address sufficiently. While a particular drug may exhibit initial success, the eventual relapse of tumor growth is due in many cases to subpopulations of cells that are either not affected by the drug mechanism, possess or acquire a greater drug resistance, or have a localized condition in their microenvironment that enables them to evade or withstand the drug. These various subpopulations may include cancer stem cells, mutated clonal variants, and tumor-associated stromal cells, as well as cells experiencing a spatially different condition such as hypoxia within a diffusion-limited tumor region. This review briefly discusses some of the many aspects of tumor heterogeneity and their potential implications for future drug design and delivery methods.
Insights
Tumor heterogeneity, with diverse cell populations, challenges drug delivery. Addressing these cellular differences is crucial for effective cancer treatments and overcoming drug resistance.
Area of Science:
- Oncology
- Pharmacology
- Biomedical Engineering
Background:
- Patient tumors exhibit cellular heterogeneity, with distinct cell populations influencing malignancy progression.
- Current tumor drug delivery research often assumes cellular uniformity, potentially leading to misleading preclinical results.
- Many promising preclinical drug candidates fail in clinical trials, possibly due to unaddressed tumor heterogeneity.
Purpose of the Study:
- To review the multifaceted aspects of tumor heterogeneity.
- To discuss the implications of tumor heterogeneity for future cancer drug design and delivery strategies.
- To highlight the limitations of current drug delivery approaches that do not account for cellular diversity within tumors.
Main Methods:
- Review of existing literature on tumor heterogeneity and drug delivery.
- Analysis of how cellular subpopulations and microenvironmental factors impact treatment efficacy.
- Discussion of specific heterogeneous cell types, including cancer stem cells and mutated clonal variants.
Main Results:
- Tumor heterogeneity is a significant factor in treatment failure and tumor relapse.
- Drug resistance can arise from subpopulations unaffected by treatment or possessing inherent resistance mechanisms.
- Localized microenvironmental conditions, such as hypoxia, contribute to treatment evasion.
Conclusions:
- Future drug design and delivery must incorporate strategies to address tumor heterogeneity.
- Overcoming cellular diversity is essential for improving the success rates of cancer therapies.
- A deeper understanding of tumor subpopulations and their interactions is needed for developing more effective treatments.
More Related Videos
08:52Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice
Published on: January 19, 2018
05:11Construction of An Orthotopic Xenograft Model of Non-Small Cell Lung Cancer Mimicking Disease Progression and Predicting Drug Activities
Published on: May 10, 2024
Related Concept Videos
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
01:24Modified-Release Drug Delivery Systems: Site-Targeted